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ADCCe protection from HIV-1 infection would provide important milestones to guide
HIV-1 vaccine development. In a proof of concept study using mucosal priming and systemic boosting, the
titer of neutralizing antibodies in sera was found to correlate with protection of mucosally exposed rhesus
macaques from SHIV infection. Mucosal priming consisted of two sequential immunizations at 12-week
intervals with replicating host range mutants of adenovirus type 5 (Ad5hr) expressing the HIV-189.6p env
gene. Following boosting with either heterologous recombinant protein or alphavirus replicons at 12-week
intervals animals were intrarectally exposed to infectious doses of the CCR5 tropic SHIVSF162p4. Heterologous
mucosal prime systemic boost immunization elicited neutralizing antibodies (Nabs), antibody-dependent
cytotoxicity (ADCC), and speciﬁc patterns of antibody binding to envelope peptides. Vaccine induced
protection did not correlate with the type of boost nor T-cell responses, but rather with the Nab titer prior to
exposure.
© 2008 Elsevier Inc. All rights reserved.Introduction
The development of a prophylactic HIV-1 vaccine appears to be the
most effective means to combat the continued transmission of human
immunodeﬁciency virus (HIV) infections estimated to be around 7000
newly infected individuals per day world wide (http://www.unaids.
org). Infection of rhesus macaques via the mucosal route with either
SIV or SHIV has been used extensively to model mucosal transmission
of HIV in humans. The development of vaccine strategies which
induce neutralizing antibodies is a particularly daunting challenge,
given the primarily mucosal route of transmission and the remarkable
diversity of HIV-1 variants (Burton et al., 2004). A limited number of
HIV/SIV vaccine strategies have revealed the potential to generate
immune responses sufﬁcient to protect against infection/disease
progression (Amara et al., 2001; Bertley et al., 2004; Crotty et al.,l rights reserved.2001; Doria-Rose et al., 2003; Mossman et al., 2004; Negri et al., 2004;
Patterson et al., 2003; Polacino et al., 1999; Zhao et al., 2003). Despite
the recent failure of a single modality T-cell based Ad5-vector vaccine
strategy to prevent infection and control virus loads in phase 2b trials
(Shiver et al., 2002) (http://www.nature.com/nature/journal/v449/
n7161/full/449390c.html), alternative Adenovirus based prime-boost
vaccine strategies for inducing neutralizing antibodies remain viable
vaccine candidates. The use of replication-competent Ad4-, 5-, and 7-
HIVenv recombinants to prime immune responses followed by protein
booster immunizations has successfully protected chimpanzees from
homologous and heterologous HIV-1 challenges (Gomez-Roman et al.,
2006b; Lubeck et al., 1997; Peng et al., 2005; Robert-Guroff et al., 1998;
Zolla-Pazner et al., 1998). In the rhesus model, these combinations
were successful as well resulting in reduced viral loads following
mucosal SIV challenge (Buge et al., 1997; Patterson et al., 2004; Zhao
et al., 2003).
Other vaccine vectors capable of inducing humoral as well as
cellular immune responses to HIV-1 or SIVmac include alphavirus
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litis (VEE) virus, Sindbis (SIN) virus, or Semliki virus (Caley et al., 1997;
Charles et al., 1997; Davis, Brown, and Johnston, 1996; Davis et al.,
2000; Johnston et al., 2005; Mossman et al., 1996; Perri et al., 2003).
Each of these vector systems offers distinct advantages based on their
unique biological properties. Chimeric alphavirus replicon particles
derived from both SIN and VEE have been engineered with the goal of
combining optimal potency and safety (Perri et al., 2003). These
chimeras combined with recombinant Env protein booster immuni-
zations elicited potent immune responses in non-human primates
(Quinnan et al., 2005; Xu et al., 2006). However, no clear immune
correlates of protection were observed.
Here we report on a “proof of concept” study incorporating
mucosal priming with Ad5hr-HIV-189.6P Env, and at 12-week intervals
boosting with either recombinant gp140 HIV-1SF162 Env protein, or
VEE/SIN chimeric alphavirus replicon particles expressing ΔV2gp140
HIV-1SF162 Env. The induction of Nabs and their contribution to
protection of Indian rhesus macaques from intrarectal (IR) challenge




BindingAb titers to a peptide pool (pp) spanning the entire gp120 of
HIV-189.6P were found after both Ad immunizations (Fig. 1A). To a
limited extent these Abs could also bind to gp120 peptides of
SHIVSF162P4 (Fig. 1A). Booster immunizations with recombinant
HIVSF162 gp140 or recombinant VEE/SIN replicons, induced SHIV-Fig. 1. Development of humoral binding responses pre and post SHIVSF162p4 challenge. (A) T
89.6p or SHIVSF162p4 or against SIV-Gag peptides were detected by ELISA. Binding titers were
Black arrows indicate immunizations and the white arrow indicates IR SHIVSF162p4 challenge.
15-mer peptides of HIV-1SF162 gp120 was tested at a serum dilution of 1:100. (C) Quality (A
various immunization regimen. Sera before 1st immunization and after the 4th immunizatiSF162P4-speciﬁc Abs, which increased in both groups after a second
booster immunization (Fig. 1A). To determine the epitopes to which
the Abs bind, individual peptide binding was studied by pepscan
analysis from sera taken at the day of challenge (Langedijk et al., 1997;
Slootstra et al.,1996). The reactivity of sera fromgroup 1 to overlapping
15-mer peptides of HIV-1SF162 revealed that Abs were induced that
bound to V1 (position 51–55 corresponding to β1–α1 region), V2
(position 60–70, corresponding to the N-terminal part and/or to the
center of the V2 loop) and V3 region (the tip of the loop andN-terminal
to the tip, position 130–140) (Fig. 1B). Analysis of sera from group 2
showed that all animals lack Abs towards the V2 region as expected
since they were boosted with a V2 deleted antigen while two animals
showed reactivity to V1 and V3 region. Serum Ri377 showed an
unusually high background, a characteristic associated with low
afﬁnity binding. Further characteristics of the induced Abs were
evaluated by determining the avidity binding towards the envelope
antigens. High avidity titers were observed in the protein boosted
group (sera taken 2 weeks pre-challenge) followed by lower avidity
titers by the VEE/SIN boosted group and the control group (Fig. 1C).
Functionality of the Abs was determined in two different assays.
Virus-neutralizing capacity of sera was measured as a function of
reduction (50% inhibition) in the standardized TZMbl luciferase
reporter assay after a single round of infection (Wei et al., 2003)
against pseudoviruses derived from clade B SHIV89.6p, SHIVSF162p3 and
SHIVSF162p4 (Li et al., 2005; Monteﬁori, 2004). After the ﬁrst booster
immunization with either recombinant protein or VEE/SIN replicons,
neutralization activity to SHIVSF162p4 developed in three of four and
two of four animals respectively, and was boosted in all animals
following the second booster immunization (Fig. 2A). Neutralizing Abs
to SHIV89.6p and the SHIVSF162p3 pseudoviruses were not observediters of binding antibodies for each animal against peptide pools covering the gp120 of
measured 2 weeks after each immunization and at various time points post-challenge.
(B) Pepscan analysis of sera from the individual animals. Reactivity with all overlapping
ntibody Avidity Index: HN4SCN concentration in M) of antibody responses induced by
on (=2 weeks pre-challenge) are shown.
Fig. 1 (continued).
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Fig. 2. Development of functional humoral responses pre and post SHIVSF162p4 challenge. (A) Neutralizing antibody responses against pseudovirus SHIVSF162p4 cl5.1B were evaluated
throughout the immunization schedule. The serum dilutions giving 50% inhibition of SHIVSF162p4 cl5.1B infection of TZMbl cells (Wei et al., 2003) are shown. Black arrows indicate
immunizations and the white arrow indicates IR SHIVSF162p4 challenge. (B) ADCC using targets coated with 89.6P gp140 protein and SF162 gp120 protein. Expressed are titers giving
speciﬁc lysis of target cells. The cut off for positive activity and determination of endpoint titer was 15.62% andwas calculated from themean of themeans of all dilutions at week 0 for
each sample plus 3 S.D.
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assays with sera from the day of challenge were conﬁrmed using
rhesus PBMC-based assays (data not shown). In addition, we
examined ADCC as collaborative functionality of the Abs induced by
these immunization protocols. Target cells were coated with either
HIV-189.6P gp140 or HIV-1SF162 gp120 protein and incubated with
serial dilutions of the sera as described (Gomez-Roman et al., 2006a).
All animals boosted with recombinant protein developed Abs which
mediated ADCC to both antigens tested as did most of the animals in
the VEE/SIN group (Fig. 2B).
In addition to humoral responses, the induction of cellular immune
responses was evaluated as well by quantiﬁcation of antigen-speciﬁc
cytokine-secreting cells (IFN-γ, IL-2 and IL-4) performed on freshly
isolated PBMCbyenzyme-linked immunospot (ELISpot) assays (Fig. 3).
Ad5hr priming resulted in IFNγ secreted cells in almost all vaccinated
animals after they have been stimulated with the homologous antigen
(Env pp of 89.6p) or by the Env pp of SF162. Boostingwith recombinant
glycoprotein (group 1) sustained high IFN-γ in all 4 animals while
boostingwith VEE/SIN replicons resulted in increased number of IFN-γ
secreting cells in most of the animals (Fig. 3). One booster immuniza-
tionwith recombinant protein resulted in an increase in IL-2 producing
cells in most of the animals (responding to both 89.6p and SF126
antigens) but these population decreased in number after the secondFig. 3. T-cell ELISpot responses elicited over time. Shown are IFN-γ (upper panels), IL-2 (mid
Ad5hr vectors followed by recombinant glycoprotein (group 1) as a booster, VEE/SIN replico
(mean numbers of SFC plus twice the standard deviations of triplicate assays with medium
SF162 gp120) are presented as the number of SFC per 106 PBMC. Arrows indicate immunizat
scale for IFN-γ differs from IL-2 and IL-4 Y-axes.booster immunization. Booster with VEE/SIN replicons had only
limited effect in the number of IL-2 producing cells. IL4 secreting
cells were not induced after prime immunizations, butmainly induced
after boosting with recombinant glycoproteins (Fig. 3).
Challenge outcome
All control animals (group 3) became infected and developed peak
viral loads between 2.6×105 and 5.6×106 RNA copies/ml in the acute
phase of infection (Fig. 4). In 3 out of 4 animals of group 1 and 2 out of
4 animals of group 2, cell-free virus could not be detected in plasma.
Furthermore, in these ﬁve animals no provirus containing PBMCs
were detected with nested DNA-PCR (Bogers et al., 1995) at weeks 2, 8
and 16 post-challenge (data not shown). The infected animals in both
immunized groups developed comparable maximum peak viral loads
as the control group. However, by 4 weeks post-challenge, vaccinees
had already controlled the infection to undetectable levels. In contrast,
the control group retained plasma viral burdens between 3.1×103 and
1.4×104 copies/ml at this same time point. Statistical comparison
between the three groups (Kruskal–Wallis test) revealed a signiﬁcant
reduction (p=0.0157) in the area under the viral load curve.
Application of Dunn's Multiple Comparison test indicated a signiﬁcant
difference between group 1 and the controls (Fig. 5A).dle panels), and IL-4 (lower panels) ELISpots from individual animals immunized with
ns (group 2) or MF59 only or empty VEE/SIN replicons (group 3). Background responses
alone) were subtracted. Responses after stimulation with either pp of 89.6p gp120 or
ions, arrow head indicates the challenge. Bold lines indicate protected animals. The Y-ax
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Fig. 4. Plasma viremia following IR challenge with SHIVSF162p4 of all animals from the
recombinant glycoprotein boost group (upper panel), the VEE/SIN boost group (middle
panel) and the control group (lower panel).
Fig. 5. Reduction in virus load under the curve up to week 16 post-challenge and
correlationwith neutralizing antibodies. (A) Area under the curve of Fig. 4 up toweek 16
post-challenge. The horizontal lines indicate the median level of area under the curve of
each group. Differences in area under the curve (log-transformed values) were analyzed
and compared using the Kruskal–Wallis test. (H=8.312; p=0.0157). (B) Correlation
between the neutralizing antibody titers at the day of challenge and the reduction in
area under the curves of Fig. 4.
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All immunized animals which exhibited Nab (IC50) titers greater
than 1/80 at the time of challenge were protected by all parameters
(negative plasma RNA and provirus in PBMC and tissues at all time
points). Protection was independent of the booster immunization
strategy. The immunized animals which did become infected devel-
oped neutralizing antibodies lower than 1/70 on the day of challenge
(1/60 for Ri108, 1/66 for Ri377 and 1/25 for Ri103; Fig. 2A). Linear
regression analysis of all macaques revealed a highly signiﬁcant
correlation between neutralization titers on the day of challenge and
protection (p=0.031) as well as reduced viral load over the 16-week
post-challenge period (Fig. 5B). This demonstrated a strong correla-tion between systemic Nab titers, independent of the two booster
immunizations, and protection against mucosal infection.
A protective correlation with cellular responses was not observed.
Vaccinated but infected animals did show equal numbers of IFN-γ
producing cells as produced by some of the protected animals. Also for
IL-2 and IL-4 secreting cells, no clear protective correlation could be
observed (Fig. 3).
Post-challenge immune responses
To further explore the role of humoral immune responses in
reduction of viral burden, we examined the anti-Env and anti-Gag Ab
kinetics following intrarectal challenge (Fig. 1). Abs which bound
SF162 peptides exhibited a booster response shortly after challenge,
followed by a decrease in almost all immunized animals over time. In
the protected animals this correlated with the absence of any plasma
RNA antigen due to complete protection from infection. Peptide
responses correlated with decreased neutralization activity in these
protected animals in contrast to infected animals. The immunized,
infected macaques exhibited increasing neutralizing titers which
reached 1/2500–1/24,000 by week 12 post-challenge, while
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responses in the unvaccinated control group reached titers of 1/4000–
1/100,000 (Fig. 2A). Notably, neutralizing Abs titers in infected
vaccinees correlated with accelerated clearance of plasma viral RNA
from circulation. No clear contribution of cellular responses to viral
clearance was observed in vaccinated infected animals (Fig. 3). In
contrast to vaccinated protected animals, all infected animals
developed systemic anti-Gag responses (Fig. 1A) and mucosal anti-
Gag responses (data not shown) after challenge. To determine
whether local infections had possibly occurred in the protected
animals, we carefully sampled multiple mucosal (colon, jejunum and
ileum) and draining lymphoid (mesenteric lymph nodes, inguinal, and
draining iliac lymph nodes) tissues on the day of necropsy (week 20).
These tissues were processed and examined for the presence of
provirus by nested DNA-PCR. Importantly, no provirus was detected in
any of these multiple tissue samples from protected vaccinees. In
contrast, the tissues taken from infected animals were routinely
provirus positive.
Discussion
Accumulating evidence indicates that an effective vaccine against
HIV will likely need to induce broad humoral, cellular and mucosal
immunity to a wide diversity of viral variants. The use of replicating
Adeno vectors as vaccine candidates has been proven to induce potent
cellular immunity and prime high-titer Abs (Peng et al., 2005; Zhao
et al., 2003). HIV-1 envelope glycoprotein is a vaccine immunogenic of
particular interest because it can serve as a potent target antigen for
both T-lymphocyte and antibody responses (Letvin et al., 2004;
Mascola et al., 2005). Especially the HIV-1SF162 gp140ΔV2 vaccine
used in this study has proven to elicit broad, potent neutralizing Abs
capacities (Barnett et al., 2001). The use of VEE/SIN chimeric alphavirus
repliconparticles has also been shown to elicit the generation of robust
neutralizing Ab responses as well as cell-mediated responses to
multiple viral antigens (Xu et al., 2006). The current proof of concept
study conﬁrmed that a mucosal adeno-priming and systemic recom-
binant glycoprotein boosting regimen is capable of eliciting immunity
sufﬁcient to reduce acute phase and set point viremia after mucosal
challenge (Patterson et al., 2004; Zhao et al., 2003). However, we
extend these observations and demonstrate that these strategies are
able to elicit neutralizing antibodies and ADCC systemically which
correlate with protection from mucosal infection.
In recent studies with VEE replicon or chimeric VEE/SIN replicon
particles as vaccine vectors, Nabs were generated either after
3 systemic immunizations with the corresponding vector only
(Johnston et al., 2005) or after a booster with recombinant gp140
protein (Xu et al., 2006). However, despite the fact that VEE or VEE/
SIN immunization resulted in reduction of viral loads in both studies
(after an intrarectal or intravenous challenge respectively), no
sterilizing immunity (Johnston et al., 2005) or limited control (Xu
et al., 2006) was achieved. Here we demonstrate that also with a
mucosal adeno-prime and systemic VEE/SIN boosting regimen, it is
possible to elicit immunity sufﬁcient to protect from mucosal
challenge. The lack of detectable viral DNA in PBMC, various mucosal
tissues and lymphoid organs in the protected animals indicate that
sterilizing immunity can be obtained. As observed with the
recombinant glycoprotein booster regimen, the VEE/SIN booster
regimen induced Nab threshold which correlated with protection
from detectable infection in the majority of immunized animals. In
the remaining immunized animals lower Nab titers correlated with
control of plasma viral RNA load.
All animals protected from infection showed peptide binding
responses towards both V1 and V3 epitopes (Fig. 1B). Binding towards
V2 epitopes does not seem to be essential because of the absence of V2
binding seen in the two protected animals which were boosted with
VEE/SIN replicons expressing the HIV-1SF162 gp140 with a V2 deletion.It is likely that the Pepscan analysis may not detect conformational
epitopes (Davis et al., 1990) especially those similar to the known
neutralizing human antibodies. The current analysis was limited to the
external envelope glycoprotein since peptides to the transmembrane
glycoprotein (gp41) were not available at the time of this study.
Srivastava et al. (2002) have shown that not only the magnitude
(binding) but also the quality (avidity) of antibody responses induced
by protein vaccination increased after subsequent boosts indicating
a maturation in the functionality of the antibodies. We have only
analyzed the avidity of the induced antibodies to SF162 gp140
after the ﬁnal immunization. This differed between both groups.
Protein boosting resulted in higher avidity as compared to the
VEE/SIN boosting.
During the prime phase, homologous binding Abs were induced in
all 8 animals (Fig. 1A) but these Abs could not neutralize homologous
SHIV89.6p (data not shown) nor SHIVSF162p4 (Fig. 2A). Already after one
booster immunization with recombinant glycoproteins, the induction
of neutralization Abs (towards the booster vaccine strain) started to
increase in parallel with the induction of IFN-γ, IL-2 as well as IL-4
secreting cells. The apparent collaborative functionality (ADCC titers)
with Nab responses was not statistically supported due to the low
numbers of ‘partially protected’ animals. Both functional assays were
conducted to determine cross-reactivity against the various vaccine
antigens. In contrast to Nab responses, which did not neutralize 89.6p,
ADCC reactivity could be determined against both antigens. The
higher titers with the 89.6p gp140 protein might have resulted from
priming with the matched Ad-recombinant. However, it is possible
that we could have seen higher titers if we used SF162 gp140 protein
as it has been shown that some epitopes for ADCC are also located on
gp41 (Ahmad et al., 1994; Nixon et al., 1992). Both humoral and
cellular responses were also induced in the VEE/SIN group but here
cellular responses were limited to IFN-γ responses. In summary, we
have shown that heterologous vaccination strategies with two
different booster immunogens induce NAbs which, when reached a
certain threshold level, correlate with protection from infection. The
induced Nab responses were limited to the booster vaccine strain. This
is in contrast to generated homologous and heterologous ADCC
antibodies as well as cellular immunity which responded after both
homologous and heterologous antigen stimulations. These studies
indicate that sequential immunizations with different envelope
antigens may not generate broad immune responses (especially the
lack of broad neutralizing activity) needed for (heterologous) efﬁcacy.
Instead, combined applications of different (envelope) antigens in
both prime as well as booster immunizations simultaneously may be
required for even broader immune responses (Demberg et al., 2007;
Patterson et al., 2004; Seaman et al., 2007).
Materials and methods
Rhesus macaques
Twelve rhesus macaques of Indian origin (9 males and 3 females;
ageN4 years; weight 5–15 kg) housed in environmentally controlled
conditions at the BPRCwere included in the study and divided in three
groups (eachwith 3males and 1 female). All animalswere negative for
SIV, simian retrovirus and simian T-cell leukemia virus. During the
course of the study, animals were checked twice daily for appetite and
general behavior and stools were checked for consistency. The
Institutional Animal Care and Use Committee approved the study
protocol according to international ethical and scientiﬁc standards
and guidelines.
Immunization and challenge schedule
Two groups of 4 animals each were primed ﬁrst via the intranasal
(IN) route and twelve weeks later via the intratracheal (IT) route. Both
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Ad5hrΔE3-HIV-189.6PEnv gp140 (Demberg et al., 2007). Animals
from the ﬁrst group were boosted twice intramuscularly (IM) with
100 μg recombinant gp140 of HIV-1SF162 in MF59 at weeks 24 and 36
(Barnett et al., 2001; Srivastava et al., 2003), while the second group
received 2× IM 108 pfu VEE/SIN replicons expressing the HIV-1SF162
gp140 with a V2 deletion (ΔV2) (Xu et al., 2006). Control animals
(group 3) received empty Ad5hr vectors followed by either adjuvant
only (n=2) or empty VEE/SIN replicons (n=2). Efﬁcacy was evaluated
utilising the IR mucosal challenge of a R5-tropic SHIVSF162p4 mucosal
challenge stock (Harouse et al., 1999) at week 44 (1 ml=1800 TCID50).
Quantitation of plasma viral RNA and proviral DNA in peripheral blood
and tissues
SHIV viral loads were determined using an adaptated version of a
published SIV-gag-based real-time PCR assay (Leutenegger et al.,
2001). The SIV-probe used was identical to the probe described by
Leutenegger et al., except that we used the quencher dye Black Hole
Quencher 2 instead of TAMRA. The forward (SIV31) and reverse
(SIV41) primers were essentially identical to primers SIV.510f and
SIV.592r (Leuteneggeret al., 2001), with minor modiﬁcations to
improve the sensitivity of the assay. The SIV31 and SIV41 primer
sequences were 5 ′-CCAGGATTTCAGGCACTGTC-3′ and 5′-
GCTTGATGGTCTCCCACACA-3′, respectively. The PCR was carried out
using the Brilliant® QRT-PCR Core Reagent Kit, 1-Step (Stratagene
Europe, Amsterdam, The Netherlands) in a 25 μl volume with ﬁnal
concentrations of 160 nM for each primer, 200 nM for the probe,
5.5 nM MgCl2, and using 10 μl RNA. RNA was reverse transcribed for
30min at 45 °C. Then, after a 10min incubation step at 95 °C, the cDNA
was ampliﬁed for 40 cycles, consisting of 15 s denaturation at 95 °C,
followed by a 1 min annealing-extension step at 60 °C. All the
reactions were carried out with an iQ™5 Multicolor Real-Time PCR
Detection System (Bio-Rad Laboratories BV, Veenendaal, The Nether-
lands). Detection limit is 100 RNA copies/ml.
DNA-PCR were performed in peripheral blood mononuclear cells
(PBMC) at different time points after challenge as well as multiple
mucosal (colon, jejunum and ileum) and draining lymphoid (mesen-
teric lymph nodes, inguinal, and draining iliac lymph nodes) tissues on
the day of necropsy (week 20) by nested DNA-PCR as described
(Bogers et al., 1995). This assay is able to detect a single proviral copy
in a background of 1 μg template DNA.
Measurement of immune responses
Antibodies speciﬁc for peptide pools (pp) spanning the entire gp120
of HIV-189.6P and for gp120 peptides of SHIVSF162P4 as well as SIV-gag
peptides (NIHAIDS Research andReferenceReagent Program,Rockville,
MD) were determined in serum using an enzyme-linked immunosor-
bent assay technique as previously described (Mooij et al., 2000).
Individual peptide binding analyses were performed on a solid
support and screening of antibody binding was studied by pepscan
analysis as described (Langedijk et al., 1997; Slootstra et al., 1996).
Furthermore, the antibody avidity index was determined using an
ammonium thiocyanate displacement (NH4SCN) ELISA as described
elsewhere in detail (Srivastava et al., 2002). Virus-neutralizing
capacity of sera was measured as a function of reduction (50%
inhibition) in the standardized TZMbl luciferase reporter assay after a
single round of infection (Wei et al., 2003) against pseudoviruses
derived from clade B SHIV89.6p, SHIVSF162p3 and SHIVSF162p4 (Li et al.,
2005; Monteﬁori, 2004).
Antibody-dependent cell-mediated cytotoxicity (ADCC) was per-
formed using the rapid ﬂuorometric assessment as described
previously (Gomez-Roman et al., 2006a). The quantiﬁcation of
antigen-speciﬁc cytokine-secreting cells was performed on freshly
isolated PBMC by IFN-γ, IL-2 and IL-4 enzyme-linked immunospot(ELISpot) assays as described (Koopman et al., 2008; Mooij et al.,
2008).
Statistical analysis
A non-parametric ANOVA Kruskal–Wallis testwas used to compare
virus load between the control group of unvaccinated animals and the
different vaccinated groups. Statistical analysis was performed for
differences in areas under the viral load curves of the various groups.
Correlation between neutralizing Ab titers and reduction in area under
the curve was calculated by using linear regression analyses.
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